A pricey Gilead HIV drug could be made for dramatically less than the company charges, researchers say

Taking stock of the drug industry, from the lab to the medicine chest

July 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Yichuan Cao/Sipa USA STAT+ | A pricey Gilead HIV drug could be made for dramatically less than the company charges, researchers say "If Gilead charges high prices and restricts access, the HIV epidemic will continue to rise," said study co-author Andrew Hill. By Ed Silverman STAT+ | U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say "There should be 0% error. These are too important to mess up. And it's an easy fix," said Sean Tu, a West Virginia University law professor. By Ed Silverman STAT+ | Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies Third Arc Bio, based in Philadelphia, plans to move one or perhaps two cancer drug candidates toward the clinic next year. By Allison DeAngelis Adobe Opinion: Fixing the reimbursement and coverage divide between 'breakthrough' drugs and medical devices First Opinion: After FDA approval, Medicare treats breakthrough medical devices differently than it treats breakthrough drugs. It's time for a change. By Richard Macary Opinion: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare's worst option First Opinion: For CMS to cover all who are overweight or obese, Novo's purchase price would be recouped in 22 months through GLP-1 purchases alone. By Melissa Barber, Joseph S. Ross, and Reshma Ramachandran

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser